<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368665">
  <stage>Registered</stage>
  <submitdate>31/05/2015</submitdate>
  <approvaldate>29/06/2015</approvaldate>
  <actrnumber>ACTRN12615000669594</actrnumber>
  <trial_identification>
    <studytitle>Pectoralis-serratus interfascial plane block vs. paravertebral block for acute post-mastectomy pain</studytitle>
    <scientifictitle>In modified radical mastectomy, does Pectoralis-serratus interfascial plane block, compared to paravertebral block, reduce postoperative opioid consumption? </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post-operative pain following modified radical mastectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Before induction of anesthesia (pre-incision), for group PS, we will give pectoralis-serratus interfascial plane block, in which we will inject 10 ml of bupivacaine 0.25% between pectoralis major and minor muscles around the pectoral nerve. and another 20 ml of bupivacaine 0.25% between pectoralis  minor and serratus anterior muscles at the level of rib 4 under ultrasonographic guidence   </interventions>
    <comparator>Before induction of anesthesia (pre-incision), for group PV, we will give thoracic paravertebral block in which we will inject 7 ml of bupivacaine 0.25% at each level (the level of T2, T4 and T6) under ultrasonographic guidence </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>postoperative 24 h morphine consumption recorded on patient chart</outcome>
      <timepoint>24 h post-operative</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The time to rescue analgesic recorded on patient chart </outcome>
      <timepoint>24 h post-operative</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intensity of pain measured by VAS score recorded on patient chart</outcome>
      <timepoint>0 h (after recovery from anesthesia), 2 h, 4h, 8h, 16 h, 24 h post-operative</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult women, American Society of Anesthesiologists (ASA) physical status class IIII, scheduled for unilateral modified radical mastectomy (MRM) with axillary evacuation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>The  exclusion criteria included patients with a known allergy to bupivacaine or morphine, bleeding disorders, anatomical abnormalities, infection in the paravertebral region, pregnancy, breast feeding, severe obesity (body mass index &gt;35 kg/m2), a history of drug or alcohol abuse and patients suffering from chronic pain or  regularly receiving analgesics.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>25/11/2013</anticipatedstartdate>
    <actualstartdate>25/11/2013</actualstartdate>
    <anticipatedenddate>1/12/2014</anticipatedenddate>
    <actualenddate>27/05/2015</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>diab fuad hetta</primarysponsorname>
    <primarysponsoraddress>organization address: south egypt cancer institute, 2 el methaque st., assuit university, assuit city, 71111, egypt</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>noha esmail ibrahim</sponsorname>
      <sponsoraddress>organization address: faculty of medicine, 1 university st., assuit university, assuit city,71111, egypt</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary> pectoralis serratus interfascial plane block (Pecs II block) in patients scheduled for MRM and axillary evacuation was compared with thoracic paravertebral block in terms of  duration of analgesia, consumption of morphine and intensity of pain in the first 24 postoperative hours.</summary>
    <trialwebsite />
    <publication>none</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SECI-IRB IORG0006563</ethicname>
      <ethicaddress>south egypt cancer institute, 2 el methaque st.,
assuit city, 71111, egypt</ethicaddress>
      <ethicapprovaldate>1/09/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>diab fuad hetta</name>
      <address>organization address: south egypt cancer institute, 2 el methaque st., assuit university, assuit city, 71111, egypt</address>
      <phone>+201091090009</phone>
      <fax />
      <email>diabhetta25@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>diab fuad hetta</name>
      <address>organization address: south egypt cancer institute, 2 el methaque st., assuit university, assuit city, 71111, egypt</address>
      <phone>+201091090009</phone>
      <fax />
      <email>diabhetta25@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>diab fuad hetta</name>
      <address>organization address: south egypt cancer institute, 2 el methaque st., assuit university, assuit city, 71111, egypt</address>
      <phone>+201091090009</phone>
      <fax />
      <email>diabhetta25@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>